Taken together, these findings confirm the role of LMW‐PTP in inducing resistance toward traditional anticancer therapy, and open new opportunities for designing innovative therapeutic approaches based on the use of specific LMW‐PTP inhibitors as chemosensitizing agents for the treatment of melanoma and other type of chemo‐ or radio‐resistant tumors. This evidence concerns the gene ACP1 and melanoma.